AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23446197 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI; 25 mg, days 8 and 22)
Number of subjects: 292
Study 22836068 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus colesevelam (3.75 g/day)
Number of subjects: 286
Study 22836068 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 286
Study 20731985 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with heavy drinkers
Number of subjects: 2649
Study 20731985 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowing heavy drinkers outside the household
Number of subjects: 2649
Study 20731985 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers within the household
Number of subjects: 2649
Study 17505461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cerclage (electively performed at 13-16 weeks gestation)
Number of subjects: 0
Study 17505461 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cerclage (urgent or emergent)
Number of subjects: 0
Study 17505461 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cerclage (McDonald technique)
Number of subjects: 0
Study 17505461 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal cerclage
Number of subjects: 0
Study 17505461 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cerclage
Number of subjects: 0
Study 15958080 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302)
Number of subjects: 257
Study 15958080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 12235612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination of the abdomen by abdominal palpation and suprapubic percussion
Number of subjects: 16
Study 12235612 — intervention group
Group type: COMPARATOR
Intervention: Portable ultrasound findings
Number of subjects: 16
Study 10616677 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment and management by specially trained physiotherapists (orthopaedic physiotherapy specialists)
Number of subjects: 481
Study 10616677 — intervention group
Group type: COMPARATOR
Intervention: Initial assessment and management by post‐Fellowship junior orthopaedic surgeons
Number of subjects: 481
Study 10616677 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist arm
Number of subjects: 481
Study 10616677 — intervention group
Group type: COMPARATOR
Intervention: Doctor arm
Number of subjects: 481
Study 7553993 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil (Group Prop)
Number of subjects: 27
Study 7553993 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/alfentanil (Group Iso)
Number of subjects: 27
Study 1443441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 2
Study 1443441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6371696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (steroids)
Number of subjects: 696
Study 6371696 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 696
Study 31803473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (anti-IL-13)
Number of subjects: 2148
Study 28805455 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support intervention (weekly calls for six weeks)
Number of subjects: 185
Study 27087149 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine candidate
Number of subjects: 400
Study 27087149 — intervention group
Group type: COMPARATOR
Intervention: Control rabies vaccine
Number of subjects: 400
Study 24419993 — intervention group
Group type: EXPERIMENTAL
Intervention: No Excuses/Sin buscar excusas (adapted VOICES intervention)
Number of subjects: 370
Study 24419993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study 22162463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandometer (intervention group)
Number of subjects: 27
Study 22162463 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 27
Study 19926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg/kg given at skin incision and 3 hours later
Number of subjects: 110
Study 19926634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study 19926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 110
Study 16931057 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-space synaesthesia individuals
Number of subjects: 4
Study 16931057 — intervention group
Group type: EXPERIMENTAL
Intervention: Month names
Number of subjects: 4
Study 16145639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 % bupivacaine plus 1 microg x ml (‐1) fentanyl
Number of subjects: 75
Study 16145639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 % bupivacaine plus 0.75 microg x ml (‐1) clonidine
Number of subjects: 75
Study 16145639 — intervention group
Group type: COMPARATOR
Intervention: 0.125 % bupivacaine
Number of subjects: 75
Study 12116326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment
Number of subjects: 194
Study 12116326 — intervention group
Group type: COMPARATOR
Intervention: Drill treatment
Number of subjects: 194
Study 10416251 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated aerosol exposure (hyperthermal 43.0 degrees C) for 10 minutes
Number of subjects: 0
Study 10416251 — intervention group
Group type: COMPARATOR
Intervention: No heated aerosol exposure (control)
Number of subjects: 0
Study 7562751 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 132
Study 7562751 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 132
Study 7562751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 132
Study 2286697 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated dose of midazolam to produce light or heavy sedation
Number of subjects: 18
Study 2286697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2286697 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (all treatment levels)
Number of subjects: 18
Study 7048922 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 0
Study 7048922 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study 31812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet M (monounsaturated fat‐enriched diet)
Number of subjects: 362
Study 31812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet P (polyunsaturated-fat enriched diet)
Number of subjects: 362
Study 31812681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet M and Diet P
Number of subjects: 362
Study 31336184 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase support with hCG (1500 IU, two injections at three days interval)
Number of subjects: 300
Study 31336184 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase support
Number of subjects: 300
Study 31336184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 29293879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hummocks burnt 6 months after the 2012 mast event
Number of subjects: 200
Study 29293879 — intervention group
Group type: COMPARATOR
Intervention: Hummocks burnt but prevented from masting by clipping inflorescences
Number of subjects: 200
Study 26784672 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 83
Study 26784672 — intervention group
Group type: COMPARATOR
Intervention: Hartmann procedure
Number of subjects: 83
Study 24178807 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide (IVTA) injection
Number of subjects: 36
Study 24178807 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated patients)
Number of subjects: 36
Study 21862138 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 49
Study 21862138 — intervention group
Group type: COMPARATOR
Intervention: Bupropion 300 mg daily
Number of subjects: 49
Study 19158194 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d)
Number of subjects: 40
Study 17482941 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 10 mg/20 mL (Group 3)
Number of subjects: 77
Study 17482941 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 10 mg/4 mL (Group 1)
Number of subjects: 77
Study 17482941 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 10 mg/10 mL (Group 2)
Number of subjects: 77
Study 17482941 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 77
Study 14693983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fast‐acting human insulin via AERx iDMS
Number of subjects: 107
Study 14693983 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous fast‐acting human insulin
Number of subjects: 107
Study 12235606 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported treadmill ambulation training (STAT)
Number of subjects: 13
Study 12235606 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention (control)
Number of subjects: 13
Study 9795350 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone twice daily
Number of subjects: 20
Study 9795350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7986457 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication with no dietary intervention
Number of subjects: 496
Study 7986457 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication with sodium restriction
Number of subjects: 496
Study 7986457 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication with weight reduction for the obese
Number of subjects: 496
Study 7986457 — intervention group
Group type: COMPARATOR
Intervention: Control group (return to antihypertensive medication)
Number of subjects: 496
Study 2590608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxpentifylline (200 mg in 10 ml saline)
Number of subjects: 8
Study 2590608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 8
Study 30039897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia restorations
Number of subjects: 40
Study 30039897 — intervention group
Group type: COMPARATOR
Intervention: Metal-Ceramic (MC) restorations
Number of subjects: 40
Study 28419982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) <64 beats/min
Number of subjects: 2060
Study 28419982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) 64-70 beats/min
Number of subjects: 2060
Study 28419982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) 71-79 beats/min
Number of subjects: 2060
Study 28419982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) >79 beats/min
Number of subjects: 2060
Study 28419982 — intervention group
Group type: EXPERIMENTAL
Intervention: RHR as a continuous variable
Number of subjects: 2060
Study 25930041 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training plus an online learning collaborative supported by expert clinicians
Number of subjects: 36
Study 25930041 — intervention group
Group type: COMPARATOR
Intervention: In-person training with local supervision
Number of subjects: 36
Study 25930041 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-supported e-learning
Number of subjects: 36
Study 25930041 — intervention group
Group type: COMPARATOR
Intervention: In-person training
Number of subjects: 36
Study 23512957 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast group (700 kcal breakfast, 500 kcal lunch, 200 kcal dinner)
Number of subjects: 100
Study 23512957 — intervention group
Group type: COMPARATOR
Intervention: Dinner group (200 kcal breakfast, 500 kcal lunch, 700 kcal dinner)
Number of subjects: 100
Study 21491295 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy (MET)
Number of subjects: 150
Study 21491295 — intervention group
Group type: COMPARATOR
Intervention: Peer-delivered 12-step facilitation (P-TSF)
Number of subjects: 150
Study 21491295 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 150
Study 21491295 — intervention group
Group type: COMPARATOR
Intervention: All groups (TAU, MET, P-TSF)
Number of subjects: 150
Study 19657294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AOX) supplementation (272 mg of alpha‐tocopherol, 400 mg of vitamin C, 30 mg of beta‐carotene, 2 mg of lutein, 400 mcg of selenium, 30 mg of zinc, and 600 mg of magnesium)
Number of subjects: 20
Study 19657294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 19657294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AOX) supplementation
Number of subjects: 20
Study 19657294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 17118826 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion scintigraphy (MPS)
Number of subjects: 102
Study 17118826 — intervention group
Group type: COMPARATOR
Intervention: Serial ECG recordings and measurements of CK-MB and cTnT
Number of subjects: 102
Study 15286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 20
Study 15286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 20
Study 15286093 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 30 mg (positive control)
Number of subjects: 20
Study 15286093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10931124 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 8
Study 10931124 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 8
Study 10931124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9443523 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily)
Number of subjects: 11
Study 9443523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8340309 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg/day)
Number of subjects: 28
Study 8340309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (gradually increased to 1.5 mg/kg/day)
Number of subjects: 28
Study 8340309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 28
Study 8340309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8340309 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and Fenfluramine
Number of subjects: 28
Study 3566109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gritti-Stokes amputations
Number of subjects: 22
Study 3566109 — intervention group
Group type: COMPARATOR
Intervention: Through-knee amputations
Number of subjects: 22
Study 31764209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Skin-to-Skin Contact (SSC)
Number of subjects: 31
Study 31764209 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Skin-to-Skin Contact (SSC)
Number of subjects: 31
Study 29502529 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding (THR) for 6 weeks
Number of subjects: 29
Study 29502529 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for 6 weeks)
Number of subjects: 29
Study 27185412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein soyabean curd
Number of subjects: 27
Study 27185412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein soyabean curd with polydextrose
Number of subjects: 27
Study 27185412 — intervention group
Group type: COMPARATOR
Intervention: Low-protein soyabean curd
Number of subjects: 27
Study 24884466 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Efficacy Scale‐International (FES‐I)
Number of subjects: 174
Study 24884466 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish FES (FES(S))
Number of subjects: 174
Study 24884466 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities‐specific Balance Confidence scale (ABC)
Number of subjects: 174
Study 24884466 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Survey of Activities and Fear of Falling in the Elderly (mSAFFE)
Number of subjects: 174
Study 22440640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage group (17 patients)
Number of subjects: 34
Study 21078810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3 (8 g/d for the first 7 days, then 4 g/d through week 24)
Number of subjects: 663
Study 21078810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 21078810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3
Number of subjects: 663
Study 18246283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S.
Number of subjects: 8255
Study 18246283 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 8255
Study 15975461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensar OptiEdge AR40e intraocular lens (sharp posterior optic edge)
Number of subjects: 53
Study 15975461 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40 intraocular lens (double-round edge design)
Number of subjects: 53
Study 12627311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (H, 14.5% O(2)) at workloads WL1, WL2, WL3
Number of subjects: 20
Study 12627311 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (N) at workloads WL1, WL2, WL3
Number of subjects: 20
Study 12627311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory response to isocapnic hypoxia (VRH)
Number of subjects: 20
Study 10556607 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal lesioned patients
Number of subjects: 2
Study 10556607 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2
Study 8908223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction at 133 mg · min‐1
Number of subjects: 21
Study 8908223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol requirement
Number of subjects: 21
Study 1713352 — intervention group
Group type: EXPERIMENTAL
Intervention: clomipramine 150 mgr/die
Number of subjects: 68
Study 1713352 — intervention group
Group type: COMPARATOR
Intervention: maprotiline/oxaprotiline 150 mgr/die
Number of subjects: 68
Study 1713352 — intervention group
Group type: COMPARATOR
Intervention: both groups (clomipramine and maprotiline/oxaprotiline)
Number of subjects: 68
Study 6126399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (60 mg daily)
Number of subjects: 26
Study 6126399 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine (10 mg daily)
Number of subjects: 26
Study 30871561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered deprescribing intervention initiated in the hospital and continued in the PAC setting
Number of subjects: 576
Study 30871561 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 576
Study 30871561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered deprescribing intervention
Number of subjects: 576
Study 28357404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) combined with pharmacological therapy
Number of subjects: 40
Study 28357404 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 40
Study 26153838 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal reinnervation
Number of subjects: 17
Study 26153838 — intervention group
Group type: COMPARATOR
Intervention: Thyroplasty
Number of subjects: 17
Study 26153838 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index 10
Number of subjects: 17
Study 24274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed herbal moisturising cream containing Arctium lappa L. seed extract
Number of subjects: 66
Study 24274317 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 66
Study 21454024 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 145
Study 21454024 — intervention group
Group type: COMPARATOR
Intervention: Voucher Control (VC)
Number of subjects: 145
Study 21454024 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 145
Study 21454024 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 145
Study 21454024 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including CM, VC, CRA, TSF)
Number of subjects: 145
Study 19170452 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI + GMET
Number of subjects: 484
Study 19170452 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI
Number of subjects: 484
Study 19170452 — intervention group
Group type: COMPARATOR
Intervention: INFO
Number of subjects: 484
Study 17370662 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid/polylactic acid bioresorbable membranes plus scaling and root planing (SRP)
Number of subjects: 30
Study 17370662 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study 15983823 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (200 ml) with atenolol (50 mg)
Number of subjects: 10
Study 15983823 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml) with atenolol (50 mg)
Number of subjects: 10
Study 11942969 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 11942969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9702617 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed fluids (setpoint 42 degrees C)
Number of subjects: 61
Study 9702617 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluids (approximately 21 degrees C)
Number of subjects: 61
Study 8657505 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion
Number of subjects: 70
Study 8657505 — intervention group
Group type: COMPARATOR
Intervention: Risk factors
Number of subjects: 70
Study 2400198 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine 4 mg b.i.d.
Number of subjects: 10